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The potential of lipopolysaccharide-binding protein to predict the severity
and prognosis of cirrhotic patients with severe sepsisBacterial translocation and episodic endotoxemia are
common phenomena in cirrhotic patients and animals.1,2
Lipopolysaccharides (LPSs), which can promote the syn-
thesis of LPS-binding protein (LBP) in the liver, intestine, and
lungs, play a central role in the pathophysiology of sepsis.3
LBP is an acute phase protein that plays an important role
in LPS signaling.3 In cirrhosis, cytokines and LBP levels
are increased and responsible for the hyperdynamic circu-
lation.4e6 Albillos et al5 reported that the subset of ascitic
cirrhotic patients with marked immune and hemodynamic
derangement can be identified by increased LBP levels. High
LBP levels have also been found to be predictive of severe
bacterial infections in cirrhotic patients with ascites.7 Previous
studies suggested that the serum level of cytokines including
LBP can serve as surrogate markers for the prognosis of cir-
rhosis.8,9 It has been reported that elevated LBP levels may be
related to bacterial passage from the gut to the circulation
without overt infection in cirrhotic patients with ascites.7 A
recent study including 286 cirrhotic patients and 100 controls
discovered that cirrhotic patients with increased serum LBP
levels were four times more likely to have severe bacterial
infection during follow-up than cirrhotic patients with normal
LBP.10
In this issue of the Journal of the Chinese Medical Asso-
ciation, Chen and colleagues11 evaluated the serum LBP,
inflammatory cytokines, and the relationship between LBP
concentrations, liver function reserve, and outcome in 58
critically ill cirrhotic patients with severe sepsis. Their study
concluded that the concentration of LBP is inversely asso-
ciated with disease severity scores and 28-day outcomes in
critically ill cirrhotic patients with severe sepsis.11 A previous
similar study reported that increased LBP levels inhibited
LPS-mediated cytokine release and prevented hepatic failure,
resulting in a significantly improved survival rate of exper-
imental mice.12 Thus, it has been suggested that low or con-
stitutive levels of LBP facilitate the recognition of LPS and
early activation of immune cells, whereas acute phase elevated
LBP levels serve to neutralize LPS to prevent overstimulation
of the immune system.2,3,5,8 Another investigation similar to
the Chen et al study11 reported that high concentrations of
LBP in serum of patients with severe sepsis or septic shock
inhibit the LPS response in human monocyte.3 Using isolated1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.10.007monocyte/sera of patients, Zweigner et al3 reported that the
inhibition of LPS effects by high concentrations of LBP is a
defense mechanism of the host in severe sepsis and bacterial
infections.
However, two recent studies reported that LBP levels were
not clearly correlated with severity and prognosis of sep-
sis.13,14 Conversely, Villar et al15 reported that serum LBP
offers a clinically useful biomarker for the identification of
patients with severe sepsis having the worst outcomes and the
highest probability of developing sepsis-induced acute respi-
ratory distress syndrome.
The discrepancies about the prognostic significance of
serum LBP level in cirrhotic and noncirrhotic patients might
be explained by the dynamic changes in serum LBP during
sepsis.11,13e15 In 180 patients with severe sepsis, serum LBP
levels were serially measured at study entry, at 48 hours, and at
7 days.14 Villar et al15 revealed that the higher LBP levels
were observed at the initial test and decreased thereafter, with
the lowest recorded at the last test (7 days). In patients with
sepsis and septic shock, Prucha et al14 measured the time-
course changes in LBP levels by repeated measurement at
3e5-day intervals for 30 days or until death. Their fifth to
seventh measurements of serum LBP levels showed a similar
trend to that in Villar et al’s study.14,15 By contrast, it is clear
that LBP can have either activating or inhibitory LPS actions
depending on its concentration.3,12 At low concentrations,
LBP typically potentiates the cells’ response to LPS by
facilitating the transfer of LPS to its receptor, whereas high
levels of LBP have been shown to inhibit cell responses to LPS
by transferring the LPS to high-density lipoproteins3 or by
facilitating the internalization of LPS without triggering
inflammatory cell stimulation.12 It is noteworthy that the
sample size of Chen et al’s study11 was relatively small
compared with previous studies.13e15 Other limitations of their
study are the lack of a noncirrhotic group and the single
measurement of serum LBP level in cirrhotic patients with
sepsis.11
This is the first study to explore the role of serum LBP level
in the prognostic values in cirrhotic patients with sepsis.11 The
current study11 provides a novel marker LBP that might help
clinicians to identify cirrhotic patients who are at risk of
deterioration and in need of timely intervention. Nonetheless,hinese Medical Association. All rights reserved.
58 Editorial / Journal of the Chinese Medical Association 77 (2014) 57e58larger sample size prospective studies are needed to clarify the
impact of serum LBP levels on the severity and prognosis at
different time points of cirrhotic patients with sepsis prior to
further clinical application.Conflicts of interest
The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this
article.References
1. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hep-
atology 2005;41:422e33.
2. Hsieh HG, Huang HC, Lee FY, Chan CY, Lee JY, Lee SD. Kinetics of
cytokine expression in cirrhotic rats. J Chin Med Assoc 2011;74:385e93.
3. Zweigner J, Gramm HJ, Singer OC, Wegscheider K, Schumann RR. High
concentrations of lipopolysaccharide-binding protein in serum of patients
with severe sepsis and septic shock inhibit the lipopolysaccharide
response in human monocytes. Blood 2001;98:3800e8.
4. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in
patients with chronic liver diseases: relationship to severity of liver dis-
eases, presence of esophageal varicies, and hyperdynamic circulation.
J Hepatol 1995;22:165e72.
5. Albillos A, de la Hera A, Gonza´lez M, Moya JL, Calleja JL, Monserrat J,
et al. Increased lipopolysaccharide binding protein in cirrhotic patients
with marked immune and hemodynamic derangement. Hepatology
2003;37:208e17.
6. Lee FY, Lu RH, Tsai YT, Lin HC, Hou MC, Li CP, et al. Plasma
interleukin-6 levels in patients with cirrhosis. Relationship to endotox-
emia, tumor necrosis factor-alpha, and hyperdynamic circulation. Scand J
Gastroenterol 1996;31:500e5.
7. Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-
binding protein prediction of severe bacterial infection in cirrhotic
patients with ascites. Lancet 2004;363:1608e10.8. Tsai MH, Peng YS, Chen YC, Lien JM, Tian YC, Fang JT, et al. Low
serum concentration of apolipoprotein A-I is an indicator of poor prog-
nosis in cirrhotic patients with severe sepsis. Heptology 2009;50:906e15.
9. Chan CC, Hwang SJ, Lee FY, Wang SS, Chang FY, Li CP, et al. Prog-
nostic value of plasma endotoxin levels in patients with cirrhosis. Scand J
Gastroenterol 1997;32:942e6.
10. Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, et al. Presence
of anti-microbial antibodies in liver cirrhosisda tell-tale sign of com-
promised immunity. PLoS One 2010;5:e12957.
11. Chen YY, Lien JM, Peng YS, Chen YC, Tian YC, Fang JT, et al. Lip-
opolysaccharide binding protein in cirrhotic patients with severe sepsis.
J Chin Med Assoc 2014;77:68e74.
12. Lamping N, Dettmer R, Schroder NWJ, Pfeil D, Hallatschek W, Burger R,
et al. LPS-binding protein protects mice from septic shock caused by LPS
or gram-negative bacteria. J Clin Invest 1998;101:2065e71.
13. Blairon L, Wittebole X, Laterre PF. Lipopolysaccharide-binding protein
serum levels in patients with severe sepsis due to gram-positive and fungal
infections. J Infect Dis 2003;187:287e91.
14. Prucha M, Herold I, Zazula R, Dubska L, Dostal M, Hildebrand T, et al.
Significance of lipopolysaccharide-binding protein (an acute phase pro-
tein) in monitoring critically ill patients. Crit Care 2003;7:R154e9.
15. Villar J, Perez-Mendez L, Espinosa E, Flores C, Blanco J, Muriel A, et al.
Serum lipopolysaccharide binding protein levels predicts severity of
lung injury and mortality in patient with severe sepsis. PLoS One
2009;4:e6818.
Ying-Ying Yang*
Division of General Medicine, Department of Medicine, Taipei
Veterans General Hospital, Taipei, Taiwan, ROC
Faculty of Medicine, National Yang-Ming University School of
Medicine, Taipei, Taiwan, ROC
*Corresponding author. Dr. Ying-Ying Yang, Division of
General Medicine, Department of Medicine,
Taipei Veterans General Hospital,
201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, ROC.
E-mail address: yangyy@vghtpe.gov.tw
